• Early Pheromones and Adult Neurodegeneration in C. elegans

  2026-09-25

  Peng and colleagues show that pheromone perception during the L1 larval stage can reshape neural signaling and accelerate neurodegeneration in adult C. elegans. Their study traces how two pheromone cues converge on interneurons and connect early environmental experience to insulin-like signaling and neuronal autophagy.

• Annexin V-Cy5 for Neurotoxicity Study Design

  2026-09-25

  The Annexin V-Cy5 Apoptosis Kit provides a rapid readout of phosphatidylserine exposure, but interpreting that signal requires more than labeling cells as apoptotic. This article uses a zebrafish microglia study to show how apoptosis measurements can strengthen causal neurotoxicity study design without confusing cell death with impaired cellular function.

• Annexin V-Cy5 Apoptosis Kit: Lab Scenarios

  2026-09-24

  Practical guidance for choosing, running, and interpreting Annexin V apoptosis detection in cell viability and neuroimmune studies. Learn how Annexin V-Cy5 Apoptosis Kit (SKU K2005) fits into a controlled workflow—and where its readout should not be mistaken for other forms of cellular dysfunction.

• DIDS: Mechanism, Evidence, and Research Use

  2026-09-24

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is an anion transport inhibitor used to investigate chloride transport and related cellular responses. Available product information reports activity across several channel and physiological models, but assay conditions and target selectivity are not fully specified, so results should be interpreted within each model.

• FOXO3–YAP Control of HCC Metabolic Reprogramming

  2026-09-23

  The study identifies FOXO3 as a suppressor of hepatocellular carcinoma metabolism, acting through direct repression of YAP to constrain both glycolysis and glutaminolysis. Cell, animal, and patient-derived organoid findings support the FOXO3/YAP axis as a candidate therapeutic strategy, while leaving questions about inducer specificity and clinical translation to further work.

• BAY-826 Workflows for Retinal Signaling Research

  2026-09-23

  BAY-826 enables concentration-controlled chemical perturbation of retinal neuron–Müller cell assays, complementing genetic knockdown and pathway readouts. This guide translates angiopoietin–PEDF findings into practical dose-response, co-culture, hypoxia, and troubleshooting workflows without treating a product specification as proof of pathway selectivity in every model.

• Early Pheromone Signals and Neurodegeneration in C. elegans

  2026-09-22

  The 2023 Cell Reports study by Peng and colleagues shows that pheromone exposure during the L1 stage can remodel neurodevelopment and accelerate adult neurodegeneration in C. elegans. Its mechanistic contribution is a defined ASK–ASI–AIA signaling circuit linking environmental chemical cues to insulin-like signaling, reduced neuronal autophagy, and later proteostasis failure.

• MVC, RhoA/ROCK1 Signaling, and Tight Junction Entry

  2026-09-22

  The reference study identifies a mechanistic link between MVC VP2, ROCK1, and tight-junction remodeling in canine WRD cells. Its findings support a model in which RhoA/ROCK1/MLC2-driven actomyosin contraction exposes Occludin and promotes viral entry, while also establishing pharmacological pathway inhibition as a strategy for dissecting MVC infection.

• ML365: TASK1 Pharmacology and Research Use

  2026-09-21

  ML365, also known as 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, is a nanomolar small-molecule probe for TASK1 potassium-channel research. Orthogonal assay data support TASK1 inhibition, while a 2024 aged-mouse study links ML365 pretreatment with reduced postoperative cognitive impairment and hippocampal NLRP3 signaling.

• AZD2461: PARP Inhibitor Assay Workflows

  2026-09-21

  AZD2461 is a novel PARP inhibitor for dissecting DNA repair, cell-cycle arrest, and drug-resistant breast cancer phenotypes. This workflow separates growth suppression from true cell killing, helping researchers select better endpoints and interpret Pgp-related resistance more accurately.

• Nanozyme Hydrogel for Intervertebral Disc Repair

  2026-09-20

  The reference study develops a ROS-responsive hydrogel containing an NPC-membrane-coated black phosphorus–cerium oxide nanozyme to disrupt the linked cycle of oxidative stress, ferroptosis, and inflammation in intervertebral disc degeneration. Its mechanistic contribution is the combination of durable ROS scavenging with suppression of the IL6/HuR/STAT3 pathway, providing a rationale for local biomaterial-based disc repair.

• Tofacitinib Workflow for JAK/STAT Research

  2026-09-19

  Tofacitinib (CP-690550) gives researchers a practical way to connect cytokine signaling blockade with lymphocyte and macrophage phenotypes. This workflow translates recent RA macrophage findings into formulation, dosing, mitochondrial, and troubleshooting strategies for reproducible immune-modulation assays.

• HyperFusion™ Polymerase for C. elegans Genotyping

  2026-09-18

  Learn how HyperFusion high-fidelity DNA polymerase can strengthen genotyping, amplicon sequencing, and difficult-template PCR workflows inspired by C. elegans neurodegeneration research. This article translates mechanistic findings into practical assay-design decisions while clearly separating biological evidence from enzyme performance.

• Separating Apoptosis from Lysosomal Stress

  2026-09-18

  A mechanistic and translational framework for using phosphatidylserine exposure to distinguish apoptosis from reversible lysosomal dysfunction in microglia and other complex research models.

• MCL-1 inhibitor A-1210477: Assay Guide

  2026-09-17

  A scenario-driven guide to using MCL-1 inhibitor A-1210477 (SKU B6011) in cell viability, proliferation, and mitochondrial apoptosis workflows. It addresses compound handling, assay compatibility, dose optimization, interpretation, and practical product selection using product data and peer-reviewed evidence.

8677 records 1/579 page Next 12345 下5页 Last page